Skip to main content

Outcomes of the IMI consultation on advanced therapies

15/09/2016

On 25 April 2016, the Innovative Medicines Initiative (IMI) launched an online consultation on advanced therapy medicinal products (ATMP) with the goal of identifying the potential of IMI as a platform for enhancing ATMP research and development. The consultation was open to all citizens and organisations, and the deadline for submitting contributions was 26 July 2016. Contributors were encouraged to consider in particular the following questions:

  • Have the key challenges that can be addressed through collaborative, public-private initiatives been properly identified?
  • Which of the proposed potential initiatives should be prioritised?
  • Are any areas missing?
  • What are the key European or national initiatives that IMI shall synergise with?

Feedback received

In total, IMI received 34 responses to the consultation. The feedback is summarised in this document . In addition, all contributions are published below.

The subject was discussed further at the IMI Stakeholder Forum on 28-29 September 2016 in Brussels, Belgium.

Comments sent by organisations

Comments sent by individuals in their personal capacity

  • Pablo Caballero
  • Hygea Salud y Nutrición, Business Association of the Health Technological Park (Granada, Spain), eHealth Chapter of Technological Cluster Granada Plaza Tecnológica, Granada eHealth Business Summit, Spain
  • Yuri D'Alessandra
  • Monzino Cardiology Centre, Italy
  • Peter Dubruel
  • University of Ghent; European Society for Biomaterials, Belgium
  • Hudecek and Einsele et al. (joint comment)
  • Full list of co-authors:
  • Michael Hudecek, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Germany
  • Hermann Einsele, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Germany
  • Attilio Bondanza, San Raffaele Scientific Institute, Milan, Italy
  • Chiara Bonini, San Raffaele Scientific Institute, Milan, Italy
  • Fabio Ciceri, San Raffaele Scientific Institute, Milan, Italy
  • Franco Locatelli, IRCCS Ospedale Pediatrico Bambino Gesu, Rome, University of Pavia, Italy
  • Mirjam Heemskerk, Leiden University Medical Center, Netherlands
  • Heike Walles, Tissue Engineering & Regenerative Medizin, Universitätsklinikum Würzburg, Germany
  • Helena Kelly
  • Royal College of Surgeons in Ireland (RCSI), Ireland
  • Gabriele Thumann
  • Hôpitaux universitaires de Genève, Service d'ophtalmologie, Switzerland
  • Patricia Vella Bonanno
  • Organisation and country note stated
  • Christof von Kalle and Manfred Schmidt (joint comment)
  • National Center for Tumor Diseases & German Cancer Research Center, Germany